Format

Send to

Choose Destination
J Clin Oncol. 2015 Nov 10;33(32):3836-8. doi: 10.1200/JCO.2015.63.1408. Epub 2015 Aug 17.

Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.

Author information

1
Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Instituto Valenciano de Oncologia, Valencia, Spain apoveda@fivo.org.
2
Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), University Pierre et Marie Curie-Sorbonne, Tenon Hospital, Hôpitaux Universitaires de l'Est Parisien-Assistance Publique-Hôpitaux de Paris, and Alliance Pour la Recherche en Cancérologie, Paris, France.
3
Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) and Klinik für Gynäkologie und Geburtshilfe, Kiel, Germany.
4
AGO and Coordinating Center for Clinical Trials, Marburg, Germany.
5
Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies and Regina Elena National Cancer Institute, Rome, Italy.
6
Belgian Gynaecological Oncology Group and University Hospital Leuven, Leuven, Belgium.
7
Dutch Gynaecological Oncology Group and University Medical Center Utrecht, Utrecht, the Netherlands.
8
Hellenic Cooperative Oncology Group and University of Athens, Athens, Greece.
9
F. Hoffmann-La Roche, Basel, Switzerland.
10
GINECO and Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France.
PMID:
26282651
DOI:
10.1200/JCO.2015.63.1408
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center